XML 54 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
OPERATING ACTIVITIES    
Net loss (including net gain or loss attributable to non-controlling interests) $ (3,885) $ (9,427)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,602 1,344
Amortization of stock-based compensation 1,236 615
Impairment of Real Estate 0 45
Equity loss from unconsolidated entities 5 78
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal 0 (22)
Changes in operating assets and liabilities:    
Restricted cash (7,392) (43)
Receivables, net 1,341 (83)
Land and other inventories (66,431) (17,087)
Assets held for sale 11,619 9,166
Prepaid expenses and other assets (1,468) 372
Accounts payable, estimated development liability, and accrued and other liabilities 7,781 1,395
Customer deposits and deferred revenues 2,407 1,668
NET CASH USED IN OPERATING ACTIVITIES (53,185) (11,935)
INVESTING ACTIVITIES    
Investment in property and equipment (409) (764)
Proceeds from sales of property and equipment 12 0
Acquisition of Royal Oak Homes (64,794) 0
Investment in unconsolidated entities 0 (95)
Proceeds from Equity Method Investment, Dividends or Distributions, Return of Capital 33 0
NET CASH USED IN INVESTING ACTIVITIES (65,158) (859)
Proceeds from Issuance of Common Stock 0 35,805
Proceeds from Issuance of Preferred Stock and Preference Stock 0 93,206
Proceeds from Issuance of Long-term Debt 200,000 0
Payments of Debt Issuance Costs 8,297 0
FINANCING ACTIVITIES    
Principal payments of 4.50% Notes (5,421) 0
Contributions from consolidated joint venture partner 193 401
Payment of withholding taxes related to restricted stock and units withheld (150) (34)
NET CASH PROVIDED BY FINANCING ACTIVITIES 186,325 129,378
INCREASE IN CASH AND CASH EQUIVALENTS 67,982 116,584
Cash and cash equivalents at beginning of period 144,727 79,815
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 212,709 $ 196,399